SUMMARY Forty-six patients with rheumatoid arthritis, 22 receiving D-penicillamine and 24 alclofenac, took part in a 6-month single-blind external observer trial to compare the efficacy and toxicity of these drugs in the treatment of severe rheumatoid arthritis. Both drugs were active and similar in their efficacy at 6 months as judged by clinical and laboratory measurements. Penicillamine was active therapeutically by 3 months, one month before alclofenac. 9 patients, 8 on alclofenac and one on D-penicillamine, had to stop treatment because of lack of effect or toxic effects. Skin rashes within the first week of treatment were a major problem with alclofenac and led to 6 withdrawals.
Alclofenac has been shown to have useful analgesic anti-inflammatory properties in the treatment of rheumatoid arthritis (Aylward, 1973) . Further studies have suggested greater efficacy than aspirin (Aylward et al., 1974) and indomethacin (Aylward et al., 1975) . It seemed appropriate to evaluate this drug in the management of severe rheumatoid arthritis.
D-penicillamine, originally discovered by Abraham et al. (1942) and first used clinically by Walshe (1956) in the treatment of Wilson's disease, has been used increasingly in the treatment of severe rheumatoid arthritis. It was first validated by the multicentre study of Andrews et al. (1973) . Subsequently its place has been established by the finding of comparable efficacy with gold (Huskisson et al., 1974) and azathioprine (Berry et al., 1976) . In view of the now established value of penicillamine, it was used as the comparative drug in this study.
Methods
A single-blind external observer trial was performed at King's College Hospital. The trial supervisor (H.B.), who was aware of the treatment allocation, was responsible for routine management, checking blood tests and urine analysis results, and listing Accepted for publication September 10, 1977 Correspondence to Dr H. Berry,.Department of Rheumatology, King's College Hospital, Denmark Hill, London SE5. unwanted side effects described by the patients. A 'blind' observer (L.F.) assessed the severity of the disease.
PATIENT SELECTION
Outpatients attending the department of rheumatology were admitted to the trial if they were over 18 years of age and had definite or classical rheumatoid arthritis, including either positive rheumatoid factor (latex titre 1/80 or more) or erosive changes on x-rays of the hands, feet or both. The disease had to be severe enough for the clinician to conventionally consider the use of gold. If the patients were receiving steroid therapy, the dosage had to have been stable for the preceding 6 months. Criteria for exclusion were (a) treatment in the preceding 6 months with gold, azathioprine, or at any time with alclofenac or D-penicillamine; (b) abnormally low white cell count or platelet count at any time; (c) evidence of renal impairment (raised blood urea or serum creatinine); (d) risk of pregnancy. Informed consent was obtained from all patients at the beginning of -the trial.
DRUGS
Alclofenac 1 g three times daily was compared with penicillamine 750 mg daily reached by 250 mg increments every 4 weeks. Patients were randomly allocated to either treatment and were only stratified for current corticosteroid administration. In addition to the trial drugs, patients continued to receive a 93 regular dose of the anti-inflammatory/analgesic drug they had been receiving before the study; this had to have been stable for the preceding month. Only paracetamol was allowed in addition. All medication was issued through normal outpatient prescribing channels.
ASSESSMENTS
The following measurements were made at the beginning of the trial and monthly for 6 months. 
LABORATORY MEASUREMENTS
All laboratory measurements were made before treatment with either penicillamine or alclofenac and at monthly intervals thereafter. The erythrocyte sedimentation rate was measured by the method of Westergren. Total and differential white cell and platelet counts were performed by standard methods. IgM, IgG, and IgA were determined by fluoronephelometry using the Technicon AIP system, and IgE determined by radioimmunoassay (Pharmacia).
Fibrinogen, ocl-acid glycoprotein, ot1-antitrypsin, x2-macroglobulin, and albumin were measured by radial immunodiffusion methods (Fahey and McKelvey, 1965) Table 1 ). 3 (2 on alclofenac and 1 on penicillamine) were withdrawn because of lack ofeffect and 6, all on alclofenac, were withdrawn during the first week of the trial because of skin rash. Restarting the drug produced a skin rash again. The mean age in the penicillamine group was 56 5 years and 55 9 years in the alclofenac group and the mean duration of disease was 9 4 years and 7-7 years respectively. (Table 6) . indomethacin. There was no evidence that it resembled the penicillamine-gold-azathioprine group in its effects (Aylward, 1973; Aylward et al., 1974 Aylward et al., , 1975 . The present results, however, showed that by 4 months patients treated with alclofenac showed significant improvement in grip strength, early morning stiffness, IgM, IgG, and haemoglobin concentrations and fall in ESR compared with the beginning of the trial.
This study confirmed the problem of skin rash related to alclofenac capsule therapy. The severe rash seemed to be an early hazard, being confined to the first week of the study. It disappeared on stopping the drug but did not recur when the patient was rechallenged. Later rashes experienced in this study were minor and on rechallenging did not recur. This was the only major problem experienced with alclofenac and is in marked contrast to the side effects seen with penicillamine which are major and potentially life-threatening hazards. These mostly occur at or beyond 9 months from the beginning of treatment and were not encountered in this 6-month study except for 2 cases of thrombocytopenia. One case has been reported of skin vasculitis which was fatal while alclofenac was being taken, but this could have been a side effect of disease rather than therapy (Billings et al., 1974) . So far the only long-term study of alclofenac failed to show serious toxicity (Aylward et al., 1974 ) but more long-term work is needed before being certain that alclofenac is free of this risk. This study did not answer this question. It must be concluded that alcofenac, as well as possessing anti-inflammatory activity similar to aspirin, also shows a penicillamine-type response and can thus be considered as an alternative treatment to gold, penicillamine, and azathioprine. Whether it should be used in this manner must depend on the results of trials conducted over a longer period, on clinical experience, and consideration of the side effects of the two drugs. 
